Connect with us

Technology

Breast Tissue Expander Market size is set to grow by USD 282.4 million from 2024-2028, Increasing prevalence of breast cancer boost the market, Technavio

Published

on

NEW YORK, July 4, 2024 /PRNewswire/ — The global breast tissue expander market size is estimated to grow by USD 282.4 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  6.78%  during the forecast period. Increasing prevalence of breast cancer is driving market growth, with a trend towards growing awareness programs for breast cancer. However, high costs associated with breast reconstruction surgeries  poses a challenge. Key market players include AbbVie Inc., Establishment Labs Holdings Inc., Global Consolidated Aesthetics Ltd., Groupe SEBBIN SAS, Guangzhou Wanhe Plastic Materials Co. Ltd., Johnson and Johnson Services Inc., PMT Corp., POLYTECH Health and Aesthetics GmbH, Sientra Inc., Silimed Industria de Implantes Ltd., and Specialty Surgical Products Inc..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

Breast Tissue Expander Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 6.78%

Market growth 2024-2028

USD 282.4 million

Market structure

Concentrated

YoY growth 2022-2023 (%)

6.23

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 36%

Key countries

US, Canada, UK, Germany, and Japan

Key companies profiled

AbbVie Inc., Establishment Labs Holdings Inc., Global Consolidated Aesthetics Ltd., Groupe SEBBIN SAS, Guangzhou Wanhe Plastic Materials Co. Ltd., Johnson and Johnson Services Inc., PMT Corp., POLYTECH Health and Aesthetics GmbH, Sientra Inc., Silimed Industria de Implantes Ltd., and Specialty Surgical Products Inc.

Market Driver

The global breast tissue expander market is witnessing growth due to the rising incidence of breast cancer and associated risk factors. Notable risk factors include genetic mutations, reproductive history, previous radiation therapy, alcohol consumption, and hormone intake. In response, various organizations are promoting education and awareness programs, as well as offering breast screening facilities for early detection. For instance, the Department of Health in Australia operates the BreastScreen Australia program, which invites women aged between 50 and 74 for free mammograms every two years. The government plans to invest USD64.3 million to extend this program to women aged 70-74. Non-government organizations are also launching podcast series to educate the public about breast cancer. These initiatives aim to reduce breast cancer mortality rates and drive market growth throughout the forecast period.

The Breast Tissue Expander market is witnessing significant growth in the Breast Reconstruction market, driven by the rising number of Breast Cancer diagnoses and increasing awareness. Reimbursements for Breast Reconstruction Treatment are also boosting market expansion. Trends include 3D-printed implants using Resomer bioresorbable polymer, silicone implants, and clinical trials for tissue expanders. Mastectomy patients opt for breast prosthetics as alternatives. Product failures and recalls have affected market players like Allergan, impacting the Breast Implants segment. Regulatory challenges and high costs are key concerns. Aging population and demand for cosmetic procedures in Ambulatory Surgical Centers, Hospitals, and Clinics drive market growth. Product shape insights include rectangular, crescent, and round expanders for various reconstructive surgeries and cosmetic procedures. Patient satisfaction, post-surgery complications, scar management, and surgical oncology are critical factors. Other applications include Forehead Skin Reconstruction, Scalp Reconstruction, Face & Neck Reconstruction. Surgical techniques and patient preferences influence market trends. 

Research report provides comprehensive data on impact of trend. For more details- Download a Sample Report

Market Challenges

The global breast tissue expander market growth may be hindered by the high cost of breast reconstruction surgeries. In developing countries like South Africa, the cost of surgery, follow-up fees, diagnostic tests, hospital stays, and breast implants add up to an average cost of USD4,500 for a mastectomy and USD3100USD10,000 for breast reconstruction. These expenses can limit patient access, particularly in countries where medical aid coverage is limited. In the US, while insurance coverage is more extensive, out-of-pocket costs remain significant, with breast reconstruction surgeries costing an average of USD10,000USD30,000 for those uninsured and USD10,000USD12,000 for insured individuals. These high costs may deter patients from seeking necessary treatment, ultimately impacting the demand for breast tissue expanders.The Breast Tissue Expander market is witnessing significant growth due to the increasing demand for reconstructive and cosmetic surgeries. Allergan dominates the Breast Implants segment, but Tissue Expanders are gaining popularity due to their use in various reconstructive procedures. Acellular Dermal Matrix is a key component in tissue expander surgeries, offering advantages in wound closure and tissue regeneration. Challenges in this market include regulatory hurdles, high costs, and patient preferences for ambulatory surgical centers, hospitals, and clinics. Product shape, such as rectangular, crescent, or round, influences surgeon preference and patient satisfaction. Reconstructive surgeries, including Forehead Skin Reconstruction, Scalp Reconstruction, and Face & Neck Reconstruction, also drive demand. Post-surgery complications, scar management, and patient satisfaction are crucial factors. Surgical oncology, Breast Conserving Surgery, and Reconstruction options further expand the market. Quality of life and patient preferences are key drivers, as an aging population seeks various aesthetic procedures.

For more insights on driver and challenges – Request a sample report!

Segment Overview

This breast tissue expander market report extensively covers market segmentation by 

End-user1.1 Hospitals1.2 Cosmetology clinics1.3 Cancer institutesProduct 2.1 Saline-filled breast tissue expanders2.2 Air-filled breast tissue expandersGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Hospitals-  The Breast Tissue Expander market is experiencing significant growth due to increasing breast reconstruction surgeries and the rising preference for aesthetic enhancements. These expanders are used to gradually expand the breast tissue prior to breast implant surgery. Major players in this market include Allergan, Sientra, and Mentor. They invest in research and development to innovate and improve their product offerings. The market is expected to continue expanding due to rising consumer awareness and affordability of these procedures.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

The Breast Tissue Expander market is witnessing significant growth due to the increasing awareness and early detection of breast cancer. Reimbursements for breast reconstruction surgeries, including tissue expanders, are driving market expansion. Mastectomy patients often require tissue expanders to prepare the chest wall for breast reconstruction or for those opting for cosmetic procedures. Innovations in medical technology, such as 3D-printed implants and Resomer bioresorbable polymers, are transforming the market. Clinical trials for new tissue expanders and alternatives, like liposuction and acellular dermal matrix, are underway. However, challenges such as capsular contracture, product failures, recalls, and regulatory hurdles pose risks. High costs and the aging population’s increasing demand for aesthetic surgeries are other market drivers. Tissue expanders are also used in reconstructive surgeries for forehead skin reconstruction, scalp reconstruction, face & neck reconstruction, and other applications. Ambulatory Surgical Centers, hospitals, and clinics are key distribution channels.

Market Research Overview

The Breast Tissue Expander market is a subsegment of the larger Breast Reconstruction market, which is driven by the increasing incidence of Breast Cancer and growing awareness about early detection and treatment. Reimbursements for breast reconstruction treatments, including tissue expanders, are a significant factor fueling market growth. Mastectomy and breast prosthetics are common breast reconstruction methods, with tissue expanders used to prepare the breast tissue for implant placement. Innovations in medical technology, such as 3D-printed implants and Resomer bioresorbable polymer, are transforming the market. Clinical trials for new products and surgical techniques are ongoing, with liposuction and capsular contracture being areas of focus. Product failures and recalls have posed challenges to market players, with Allergan’s breast implant scandal being a notable example. The Breast Implants segment, which includes tissue expanders, accounts for a significant share of the market. Reconstructive surgeries and cosmetic procedures are key application areas, with patient preferences and quality of life being crucial factors. Regulatory challenges and high costs are major market restraints, with ambulatory surgical centers, hospitals, and clinics being the primary end-users. Product shape, including rectangular, crescent, and round, is a significant factor influencing patient satisfaction and post-surgery complications. Other applications of tissue expanders include forehead skin reconstruction, scalp reconstruction, face & neck reconstruction, and breast augmentation. Surgical oncology, breast conserving surgery, and reconstruction options are also areas of interest in the market. Patient satisfaction, scar management, and surgical techniques are critical factors influencing market growth. Overall, the Breast Tissue Expander market is expected to grow significantly in the coming years, driven by increasing demand for breast reconstruction treatments, technological innovations, and patient preferences.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

End-userHospitalsCosmetology ClinicsCancer InstitutesProductSaline-filled Breast Tissue ExpandersAir-filled Breast Tissue ExpandersGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/breast-tissue-expander-market-size-is-set-to-grow-by-usd-282-4-million-from-2024-2028–increasing-prevalence-of-breast-cancer-boost-the-market-technavio-302188968.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

BRIDGE Appoints Morgan Jetto As Executive Vice President, Business Development & Ecosystems

Published

on

By

Industry Veteran to Lead Strategic Partnerships as BRIDGE Extends Its Position as the Trusted Partner for Audience Targeting, Curation, and Agentic Audience Targeting

NEW YORK, Apr. 21, 2026 /PRNewswire/ — BRIDGE, the verified people-data layer for advertising and marketing, today announced the appointment of Morgan Jetto as Executive Vice President, Business Development & Ecosystems. In this newly created role, Jetto will drive BRIDGE’s partnership strategy, expand its ecosystem of data and media integrations, and accelerate revenue growth across its key growth verticals as demand for verified data surges.

“Morgan brings a rare combination of deep industry relationships, strategic vision, and hands-on execution,” said Robert Rose, CEO of BRIDGE. “The industry is moving toward verified identity, curated audiences advertisers can trust, and agentic audience targeting that needs real, consent-audited people data underneath it. BRIDGE sits at the center of all three shifts, and Morgan’s leadership will help us extend that foundation to every agency, platform, and AI builder who needs it.”

Jetto joins BRIDGE from Verve Group, where he served as Senior Vice President and General Manager. His career spans nearly two decades of proven senior roles in AdTech and MarTech — including global partnerships at Yahoo, client leadership at GroupM, as well as board and advisory roles — with a consistent focus on building partnerships at the intersection of data, media, and emerging technology.

“BRIDGE has built something genuinely differentiated — a verified, people-based data foundation the industry urgently needs, and an architecture built for the next generation of agentic audience targeting,” said Jetto. “I’m excited to join at this critical and pivotal moment and help expand the ecosystem of partners, platforms, and clients who can benefit from the differentiated foundation BRIDGE has built— and I’m just getting started.”

BRIDGE is the verified people-data layer for advertising and marketing — the trusted foundation agencies, brands, platforms, and AI builders rely on for audience targeting and curation. Every record is a real person, verified through the Data Safe™ methodology. The CONNECT platform activates the same verified person across CTV, digital, social, email, audio, programmatic, and direct mail, and is built for agentic audience targeting through Connect MCP. People Match™ closes the loop with deterministic attribution. BRIDGE powers 160,000+ campaigns annually and has been ranked #1 for data accuracy by Truthset — an independent third party — for five consecutive years. The graph includes 412.9M verified consumers and business people and 679.8M permission-based emails, anchored on SOC2, SOC3, and HIPAA compliance. Learn more at www.thebridgecorp.com.

Media Contact

Karen Nordahl
BRIDGE
Director, Human Resources 
connect@thebridgecorp.com
+1 ( 212) 991-5633

View original content to download multimedia:https://www.prnewswire.com/news-releases/bridge-appoints-morgan-jetto-as-executive-vice-president-business-development–ecosystems-302749323.html

SOURCE BRIDGE

Continue Reading

Technology

SOLOWIN HOLDINGS Expects Revenue in the Range of $27 Million to $29 Million, Approximately 10x Year-over-Year Growth for the Fiscal Year Ended March 31, 2026 Based on Preliminary Unaudited Results

Published

on

By

HONG KONG, April 21, 2026 /PRNewswire/ — SOLOWIN HOLDINGS (Nasdaq: AXG) (“SOLOWIN,” the “Company,” or “we”), a leading financial technology firm bridging traditional and digital assets, today announced certain preliminary, unaudited financial results for the fiscal year ended March 31, 2026. Driven by the rapid expansion of its digital asset tokenization, stablecoin infrastructure, and AI-powered services, the Company delivered exceptional top-line growth for the fiscal year ended March 31, 2026, as it advances its global framework compliance and institutional-grade service strategy.

The preliminary financial results described in this press release are unaudited and based on management’s current estimates of our results for the fiscal year ended March 31, 2026. These figures are subject to the completion of our customary year-end financial closing procedures and audit by the Company’s independent registered public accounting firm. No assurance can be given that final audited results will not differ materially from these preliminary estimates, and any such differences could be significant. We expect to file our audited financial results for the fiscal year ended March 31, 2026, with the U.S. Securities and Exchange Commission in our Annual Report on Form 20-F, which is expected to be filed in July 2026.

Overall Performance

Revenue increased nearly tenfold year over year to between $27 million and $29 million for the fiscal year ended March 31, 2026.

Net loss was in the range of $11 million to $13 million, reflecting continued investment in technology, compliance, and global business expansion.

Financial Condition

As of March 31, 2026, cash and cash equivalents increased to between $14 million and $16 million.

Net cash used in operating activities was in the range of $12 million to $14 million for the year ended March 31, 2026. The increase in receivables from customers was the primary driver of the cash used in operating activities during the current period.

Net cash provided by investing activities was in the range of $1 million to $3 million for the year ended March 31, 2026, mainly consisting of cash and bank balances arising from acquisition of subsidiaries, partly offset by purchases of short-term investments.

Net cash provided by financing activities increased to between $18 million and $20 million for the year ended March 31, 2026, mainly representing the proceeds from capital injections from investors.

Strategic Overview

Against a backdrop of accelerating institutional adoption, maturing global regulation, and deepening integration of AI and blockchain, SOLOWIN has further consolidated its position as a fully compliant, vertically integrated digital financial platform, with a clear dual-token strategy focused on Digital Asset Tokens and AI Tokens. The Company’s ecosystem spans stablecoin issuance and payments, asset tokenization, securities trading and asset management, as well as AI-powered services.

Management Commentary

Mr. Lok Ling Ngai, Chief Executive Officer and Chairman of SOLOWIN, stated: “Fiscal 2026 marks a transformative year for SOLOWIN. Achieving tenfold revenue growth represents more than a financial milestone, it validates the strength of our dual-token strategy and underscores the accelerating global demand for compliant, institutional-grade digital asset infrastructure. We are uniquely positioned at the convergence of three structural shifts reshaping our industry: the advancement of regulatory frameworks, the rapid adoption of tokenization, and the integration of AI with blockchain technologies.”

“Guided by our mission ‘Mobilizing Tokens 24/7,’ we are building a secure, efficient, and fully regulated digital financial ecosystem. Over the past year, we have significantly strengthened and expanded our stablecoin and payment infrastructure, scaled our asset tokenization capabilities, and enhanced our AI-powered services. Together, these efforts reinforce and deepen our licensed platform advantages across Hong Kong, Bahrain, and other key global markets.”

“We see ourselves as more than a technology company — we are a trusted bridge connecting traditional finance and the decentralized economy. As global regulatory frameworks continue to mature and institutional adoption accelerates, we remain steadfast in our commitment to compliance, transparency, and responsible innovation. Our goal is to deliver sustainable, long-term value for our clients, partners, and shareholders — and help to power the future of finance.”

About SOLOWIN HOLDINGS

SOLOWIN HOLDINGS (NASDAQ: AXG) is a leading global regulated fintech company. Established in 2016, AXG combines blockchain and artificial intelligence technologies to operate a fully compliant dual-token digital economy super platform.

Guided by the mission “Mobilizing Tokens 24/7,” the Company focuses on tokenization and operates two core business pillars: Digital Asset Tokens and AI Tokens. Its offerings span stablecoin issuance and payments, asset tokenization, securities trading and asset management, as well as AI-powered services including cloud infrastructure, Know-Your-Agent verification, and token router.

Through its integrated ecosystem, including AXCOIN, AXONE, FERION, SOLOMON, SCION, and KOVAR, AXG empowers global institutions and investors to capitalize on the rapid growth of the dual-token economy.

For more information, visit the Company’s website at https://www.alloyx.com or Investor Relations webpage at https://ir.alloyx.com

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. The Company has attempted to identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) including the “Risk Factors” section of the Company’s most recent Annual Report on Form 20-F as well as in its other reports filed or furnished from time to time with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC, which are available for review at www.sec.gov.

For investor and media inquiries please contact:

SOLOWIN HOLDINGS
Investor Relations Department
Email: ir@solowin.io

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

View original content:https://www.prnewswire.com/news-releases/solowin-holdings-expects-revenue-in-the-range-of-27-million-to-29-million-approximately-10x-year-over-year-growth-for-the-fiscal-year-ended-march-31-2026-based-on-preliminary-unaudited-results-302749291.html

SOURCE SOLOWIN HOLDINGS

Continue Reading

Technology

Chemours Announces Dates for First Quarter 2026 Earnings Release and Webcast Conference Call

Published

on

By

WILMINGTON, Del., April 21, 2026 /PRNewswire/ — The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) today announced that the Company expects to issue its first quarter 2026 financial results after market on Tuesday, May 5, 2026.

The Company expects to hold its conference call to discuss its first quarter 2026 financial results at 8:00 a.m. Eastern Time on Wednesday, May 6, 2026. The call is open to the public and can be accessed via the webcast information below. The webcast and materials can be accessed by visiting the “Events and Presentations” section of the Investor Relations section of Chemours’ website at investors.chemours.com.

Conference Call: Please visit investors.chemours.com for a link to the live webcast and to view the accompanying slides.

Replay: A webcast replay will be available at investors.chemours.com.

About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers’ biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn

CONTACTS:

INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3300
investor@chemours.com

NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
media@chemours.com  

View original content to download multimedia:https://www.prnewswire.com/news-releases/chemours-announces-dates-for-first-quarter-2026-earnings-release-and-webcast-conference-call-302749283.html

SOURCE The Chemours Company

Continue Reading

Trending